P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-Action

Chemotherapy is still the cornerstone for malaria control. Developing drugs against Plasmodium parasites and monitoring their efficacy requires methods to accurately determine the parasite killing rate in response to treatment. Commonly used techniques essentially measure metabolic activity as a proxy for parasite viability. However, these approaches are susceptible to artefacts, as viability and metabolism are two parameters that are coupled during the parasite life cycle but can be differentially affected in response to drug actions. Moreover, traditional techniques do not allow to measure the speed-of-action of compounds on parasite viability, which is an essential efficacy determinant. We present here a comprehensive methodology to measure in vitro the direct effect of antimalarial compounds over the parasite viability, which is based on limiting serial dilution of treated parasites and re-growth monitoring. This methodology allows to precisely determine the killing rate of antimalarial compounds, which can be quantified by the parasite reduction ratio and parasite clearance time, which are key mode-of-action parameters. Importantly, we demonstrate that this technique readily permits to determine compound killing activities that might be otherwise missed by traditional, metabolism-based techniques. The analysis of a large set of antimalarial drugs reveals that this viability-based assay allows to discriminate compounds based on their antimalarial mode-of-action. This approach has been adapted to perform medium throughput screening, facilitating the identification of fast-acting antimalarial compounds, which are crucially needed for the control and possibly the eradication of malaria.

[1]  David L. Tabb,et al.  A proteomic view of the Plasmodium falciparum life cycle , 2002, Nature.

[2]  M. Mota,et al.  Simple flow cytometric detection of haemozoin containing leukocytes and erythrocytes for research on diagnosis, immunology and drug sensitivity testing , 2011, Malaria Journal.

[3]  P. Rosenthal,et al.  Multiple Antibiotics Exert Delayed Effects against the Plasmodium falciparum Apicoplast , 2007, Antimicrobial Agents and Chemotherapy.

[4]  A. Vaidya,et al.  Mitochondrial Electron Transport Inhibition and Viability of Intraerythrocytic Plasmodium falciparum , 2010, Antimicrobial Agents and Chemotherapy.

[5]  G. Harding,et al.  The Postantibiotic Effect: A Review of in Vitro and in Vivo Data , 1991, DICP : the annals of pharmacotherapy.

[6]  M. Enserink,et al.  Did They Really Say ... Eradication? , 2007, Science.

[7]  P. Rathod,et al.  Clonal viability measurements on Plasmodium falciparum to assess in vitro schizonticidal activity of leupeptin, chloroquine, and 5-fluoroorotate , 1993, Antimicrobial Agents and Chemotherapy.

[8]  Loraine Ja World population situation during 1973. , 1974 .

[9]  Peter G. Schultz,et al.  In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen , 2008, Proceedings of the National Academy of Sciences.

[10]  Xavier C Ding,et al.  Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. , 2011, Trends in parasitology.

[11]  V. Barton,et al.  The Molecular Mechanism of Action of Artemisinin—The Debate Continues , 2010, Molecules.

[12]  C. Wongsrichanalai,et al.  Histidine-Rich Protein II: a Novel Approach to Malaria Drug Sensitivity Testing , 2002, Antimicrobial Agents and Chemotherapy.

[13]  James R. Brown,et al.  Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.

[14]  V. Dev,et al.  A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India. , 2005, The American journal of tropical medicine and hygiene.

[15]  J. Baird,et al.  Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. , 2009, The Lancet. Infectious diseases.

[16]  Ogobara K. Doumbo,et al.  A Research Agenda to Underpin Malaria Eradication , 2011, PLoS medicine.

[17]  M. Petzold,et al.  Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies , 2008, BMC Infectious Diseases.

[18]  N. White Artemisinin resistance—the clock is ticking , 2010, The Lancet.

[19]  M. Gatton,et al.  Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure , 2011, Malaria Journal.

[20]  L. Gerena,et al.  Assessment and Continued Validation of the Malaria SYBR Green I-Based Fluorescence Assay for Use in Malaria Drug Screening , 2007, Antimicrobial Agents and Chemotherapy.

[21]  H. Vial,et al.  Reliability of Antimalarial Sensitivity Tests Depends on Drug Mechanisms of Action , 2010, Journal of Clinical Microbiology.

[22]  M. Makler,et al.  Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. , 1993, The American journal of tropical medicine and hygiene.

[23]  J. Daily,et al.  A non-radioactive DAPI-based high-throughput in vitro assay to assess Plasmodium falciparum responsiveness to antimalarials--increased sensitivity of P. falciparum to chloroquine in Senegal. , 2010, The American journal of tropical medicine and hygiene.

[24]  C. Canfield,et al.  Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. , 1999, The Journal of infectious diseases.

[25]  W. Trager,et al.  Human malaria parasites in continuous culture. , 1976, Science.

[26]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[27]  T. S. St. Pierre,et al.  A comparative study of a flow-cytometry-based assessment of in vitro Plasmodium falciparum drug sensitivity , 2009, Malaria Journal.

[28]  Lorenz von Seidlein,et al.  Artemisinin resistance: current status and scenarios for containment , 2010, Nature Reviews Microbiology.

[29]  T. Davis,et al.  Comparison of artemether-lumefantrine with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in eastern Nepal. , 2007, The American journal of tropical medicine and hygiene.

[30]  J. Wiesner,et al.  Delayed parasite elimination in human infections treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro. , 2007, International journal for parasitology.

[31]  Anang A. Shelat,et al.  Chemical genetics of Plasmodium falciparum , 2010, Nature.

[32]  L. Sax,et al.  DRUG SENSITIVITY OF PLASMODIUM FALCIPARUM An In-vitro Microtechnique , 1978, The Lancet.

[33]  B. Petros,et al.  Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia , 2009, Malaria Journal.

[34]  M. Enserink,et al.  Malaria. Did they really say ... eradication? , 2007, Science.

[35]  Organização Mundial de Saúde,et al.  World malaria report 2011 , 2011 .

[36]  M. Gatton,et al.  Artemisinin‐induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure. , 2010, The Journal of infectious diseases.

[37]  J. Haynes,et al.  Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique , 1979, Antimicrobial Agents and Chemotherapy.

[38]  Yongyuth Yuthavong,et al.  A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.

[39]  H. Webster,et al.  Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. , 1996, The American journal of tropical medicine and hygiene.

[40]  Joanne M. Morrisey,et al.  Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum , 2007, Nature.

[41]  C. Wongsrichanalai,et al.  Malaria drug-sensitivity testing: new assays, new perspectives. , 2003, Trends in parasitology.

[42]  H. Vial,et al.  Use of radioactive ethanolamine incorporation into phospholipids to assess in vitro antimalarial activity by the semiautomated microdilution technique , 1992, Antimicrobial Agents and Chemotherapy.

[43]  V. Barton,et al.  Inhibiting Plasmodium cytochrome bc1: a complex issue. , 2010, Current opinion in chemical biology.

[44]  Weltgesundheitsorganisation World malaria report , 2005 .

[45]  N. White,et al.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo , 1997, Antimicrobial agents and chemotherapy.

[46]  P Chiodini,et al.  Immunocapture diagnostic assays for malaria using Plasmodium lactate dehydrogenase (pLDH). , 1999, The American journal of tropical medicine and hygiene.

[47]  Nicholas J. White,et al.  Activities of Artesunate and Primaquine against Asexual- and Sexual-Stage Parasites in Falciparum Malaria , 2004, Antimicrobial Agents and Chemotherapy.

[48]  C. Davis,et al.  Preclinical drug metabolism and pharmacokinetic evaluation of GW844520, a novel anti-malarial mitochondrial electron transport inhibitor. , 2006, Journal of pharmaceutical sciences.

[49]  P. Kremsner,et al.  Curing of chloroquine-resistant malaria with clindamycin. , 1993, The American journal of tropical medicine and hygiene.

[50]  David M. Shackleford,et al.  Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. , 2009, Journal of medicinal chemistry.